Embecta Corp (EMBC) Stock Price, Quote & News

Company Profile

Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headqu...

Industry: Medical Instruments & Supplies

Sector: Healthcare

Phone: 862 401 0000

Website: www.embecta.com

Address:

300 Kimball Drive, Suite 300, Parsippany, United States

LordWorld May. 13 at 8:56 PM

$EMBC If the situation worsens, they may put themselves up for sale. The buyout price, based on market capitalization, is a minimum of $10 and a maximum of $28 per share. This includes the company's debt.

0 · Reply

LordWorld May. 13 at 8:52 PM

$EMBC The probability of bankruptcy by the end of the year is 1%. 😂

0 · Reply

JOHNNY_DANGER May. 13 at 8:29 PM

$EMBC Is it possible that they file for chapter 7 bk by years end ?

1 · Reply

assetmogul2 May. 13 at 8:03 PM

$EMBC holding 170k shares and will decide what I am doing after hearing this speech tonight

0 · Reply

javiarza May. 13 at 7:59 PM

$EMBC 500 shares at 3,13$ - average down. Let’ s see the conference now!

0 · Reply

derdo May. 13 at 7:54 PM

$EMBC as i said, garbage

0 · Reply

OrangeJoolius May. 13 at 7:51 PM

$EMBC As I said, max short.

2 · Reply

showmethemoney75 May. 13 at 7:47 PM

$EMBC

0 · Reply

derdo May. 13 at 7:42 PM

$EMBC me warned but nobody listened. garbage

0 · Reply

LordWorld May. 13 at 7:33 PM

$EMBC I'm betting on this conference! Which will begin immediately after the market closes.

0 · Reply

embecta to Participate at the 2026 BofA Securities Global Health Care Conference

2026-05-07T06:57:11.000Z - 6 days ago

Embecta price target lowered to $5 from $12 at Mizuho

May 6, 2026, 9:41 AM EDT - 7 days ago

Embecta Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

May 5, 2026, 8:00 AM EDT - 8 days ago

Embecta Earnings Call Transcript: Q2 2026

2026-05-05T11:06:10.000Z - 8 days ago

Embecta lowers FY26 adjusted EPS view to $1.55-$1.75 from $2.80-$3.00

2026-05-05T10:48:58.000Z - 8 days ago

Embecta reports Q2 adjusted EPS 27c, consensus 42c

May 5, 2026, 6:30 AM EDT - 8 days ago

embecta Announces Quarterly Cash Dividend

May 5, 2026, 6:30 AM EDT - 8 days ago

Embecta Corp. Reports Second Quarter Fiscal 2026 Financial Results

2026-04-29T17:50:52.000Z - 14 days ago

Embecta management to meet virtually with BTIG

Apr 21, 2026, 5:00 PM EDT - 21 days ago

embecta to Report Fiscal Second Quarter Financial Results

2026-04-13T14:41:50.000Z - 4 weeks ago

Embecta price target lowered to $12 from $14 at Mizuho

2026-04-13T11:55:26.000Z - 4 weeks ago

Embecta price target lowered to $22 from $25 at BTIG

2026-03-19T10:46:35.000Z - 7 weeks ago

Embecta acquiring Owen Mumford Holdings

Mar 19, 2026, 6:30 AM EDT - 7 weeks ago

embecta Announces Definitive Agreement to Acquire Owen Mumford Holdings Limited

2026-02-11T21:21:38.000Z - 3 months ago

Embecta elects CEO Devdatt Kurdikar as chairman

Feb 11, 2026, 4:10 PM EST - 3 months ago

embecta names new Chairman of the Board and Lead Independent Director

Feb 5, 2026, 8:00 AM EST - 3 months ago

Embecta Earnings Call Transcript: Q1 2026

2026-02-05T11:42:06.000Z - 3 months ago

Embecta reports Q1 adjusted EPS 71c, consensus 67c

2026-02-05T11:41:02.000Z - 3 months ago

Embecta backs FY26 adjusted EPS view $2.80-$3.00, consensus $2.89

Feb 5, 2026, 6:30 AM EST - 3 months ago

Embecta Corp. Reports First Quarter Fiscal 2026 Financial Results

Jan 22, 2026, 5:00 PM EST - 3 months ago

embecta to Report Fiscal First Quarter Financial Results

Jan 14, 2026, 5:15 PM EST - 4 months ago

Embecta Transcript: 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 5:00 PM EST - 5 months ago

embecta to Participate at the J.P. Morgan 2026 Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 6 months ago

Embecta Earnings Call Transcript: Q4 2025

2025-11-25T11:35:52.000Z - 6 months ago

Embecta reports Q4 adjusted EPS 50c, consensus 46c

2025-11-25T11:35:41.000Z - 6 months ago

Embecta sees FY26 adjusted EPS $2.80-$3.00, consensus $2.95

Nov 25, 2025, 6:30 AM EST - 6 months ago

Embecta Corp. Reports Fiscal 2025 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2026 Financial Guidance

2025-11-17T22:05:09.000Z - 6 months ago

Embecta chairman David Melcher to retire, CEO Devdatt Kurdikar to succeed

Nov 17, 2025, 5:00 PM EST - 6 months ago

embecta announces changes to Board of Directors

Nov 14, 2025, 6:30 AM EST - 6 months ago

embecta Announces Major New Commitment to Direct Relief on World Diabetes Day

Nov 11, 2025, 5:00 PM EST - 6 months ago

embecta to Report Fiscal Fourth Quarter and Full Year 2025 Financial Results

2025-09-09T14:20:26.000Z - 8 months ago

Embecta management to meet with BTIG

Sep 4, 2025, 3:00 PM EDT - 8 months ago

Embecta Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Aug 26, 2025, 5:00 PM EDT - 9 months ago

embecta to Participate in Investor Events

2025-08-08T18:45:13.000Z - 9 months ago

Embecta price target lowered to $11 from $18 at BofA

Aug 8, 2025, 8:00 AM EDT - 9 months ago

Embecta Earnings Call Transcript: Q3 2025

2025-08-08T10:41:58.000Z - 9 months ago

Embecta raises FY25 adjusted EPS view to $2.90-$2.95 from $2.70-$2.90

2025-08-08T10:35:32.000Z - 9 months ago

Embecta reports Q3 adjusted EPS $1.12 vs. 74c last year

Aug 8, 2025, 6:30 AM EDT - 9 months ago

Embecta Corp. Reports Third Quarter Fiscal 2025 Financial Results

Jul 24, 2025, 5:00 PM EDT - 10 months ago

embecta to Report Fiscal Third Quarter 2025 Financial Results

2025-07-16T11:42:06.000Z - 10 months ago

Embecta price target lowered to $12 from $13 at Mizuho

Jun 10, 2025, 1:20 PM EDT - 1 year ago

Embecta Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 5, 2025, 4:55 PM EDT - 1 year ago

Embecta Transcript: Jefferies Global Healthcare Conference 2025

2025-05-23T12:51:11.000Z - 1 year ago

Embecta price target lowered to $13 from $15 at Mizuho

2025-05-23T11:25:30.000Z - 1 year ago

Embecta price target lowered to $25 from $26 at BTIG

May 22, 2025, 9:00 AM EDT - 1 year ago

Embecta Transcript: Investor Day 2025

May 22, 2025, 6:30 AM EDT - 1 year ago

embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day

May 9, 2025, 8:00 AM EDT - 1 year ago

Embecta Earnings Call Transcript: Q2 2025

May 9, 2025, 6:30 AM EDT - 1 year ago

Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

Apr 28, 2025, 7:30 AM EDT - 1 year ago

Embecta to host Analyst and Investor Day on May 22, 2025

Apr 21, 2025, 5:00 PM EDT - 1 year ago

embecta to Report Fiscal Second Quarter 2025 Financial Results

Apr 1, 2025, 8:05 AM EDT - 1 year ago

Mayo Clinic Proceedings Publishes New Global Insulin Injection Recommendations

Feb 18, 2025, 5:00 PM EST - 1 year ago

embecta to Participate at the J.P. Morgan Global Leveraged Finance Conference

Feb 6, 2025, 8:00 AM EST - 1 year ago

Embecta Earnings Call Transcript: Q1 2025

Feb 6, 2025, 6:30 AM EST - 1 year ago

Embecta Corp. Reports First Quarter Fiscal 2025 Financial Results

Jan 23, 2025, 5:00 PM EST - 1 year ago

embecta to Report Fiscal First Quarter 2025 Financial Results

Jan 15, 2025, 10:30 AM EST - 1 year ago

Embecta Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Dec 19, 2024, 5:00 PM EST - 1 year ago

embecta to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 27, 2024, 4:38 PM EST - 1 year ago

Overlooked Stock: EMBC

Nov 26, 2024, 8:00 AM EST - 1 year ago

Embecta Earnings Call Transcript: Q4 2024

Nov 26, 2024, 6:30 AM EST - 1 year ago

Embecta Corp. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results; Provides Initial Fiscal Year 2025 Financial Guidance; Discontinues Insulin Patch Pump Program; and Announces Restructuring to Streamline Operations and Reduce Costs

Nov 12, 2024, 5:31 PM EST - 1 year ago

UPDATE - embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

Nov 12, 2024, 5:00 PM EST - 1 year ago

embecta to Report Fiscal Fourth Quarter and Full Year 2024 Financial Results

Nov 7, 2024, 6:30 AM EST - 1 year ago

embecta Celebrates National Diabetes Awareness Month by Ringing Nasdaq Closing Bell

Sep 16, 2024, 2:00 PM EDT - 1 year ago

Embecta Transcript: CL King's 22nd Annual Best Ideas Conference 2024

Sep 5, 2024, 2:35 PM EDT - 1 year ago

Embecta Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 3, 2024, 6:30 AM EDT - 1 year ago

embecta Announces FDA Clearance of its Disposable Patch Pump for Insulin Delivery Informed by the Unique Needs of People with Type 2 Diabetes

Aug 9, 2024, 8:00 AM EDT - 1 year ago

Embecta Earnings Call Transcript: Q3 2024

Aug 9, 2024, 6:30 AM EDT - 1 year ago

Embecta Corp. Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 8:05 AM EDT - 1 year ago

Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company

Jul 18, 2024, 5:00 PM EDT - 1 year ago

embecta to Report Fiscal Third Quarter 2024 Financial Results

Jun 24, 2024, 6:30 AM EDT - 2 years ago

embecta-sponsored Abstracts Presented at American Diabetes Association's 84th Scientific Sessions Highlight Unmet Need for Patch Pumps with 300u Insulin Reservoir

Jun 20, 2024, 7:30 AM EDT - 2 years ago

Zimmer Biomet Announces Appointment of Devdatt Kurdikar to Board of Directors

May 17, 2024, 4:30 PM EDT - 2 years ago

Embecta (EMBC) CEO on Diabetes Treatment Market

May 16, 2024, 1:00 PM EDT - 2 years ago

Embecta Transcript: BofA Securities 2024 Health Care Conference

May 9, 2024, 8:00 AM EDT - 2 years ago

Embecta Earnings Call Transcript: Q2 2024

May 9, 2024, 6:30 AM EDT - 2 years ago

Embecta Corp. Reports Second Quarter Fiscal 2024 Financial Results

Apr 23, 2024, 5:00 PM EDT - 2 years ago

embecta to Report Fiscal Second Quarter 2024 Financial Results

Mar 6, 2024, 6:00 AM EST - 2 years ago

embecta-sponsored Educational Symposium and Abstracts at ATTD Highlight Role of Insulin Pumps in the Management of Type 2 Diabetes

Feb 9, 2024, 8:00 AM EST - 2 years ago

Embecta Earnings Call Transcript: Q1 2024

Feb 9, 2024, 6:30 AM EST - 2 years ago

Embecta Corp. Reports First Quarter Fiscal 2024 Financial Results

Feb 7, 2024, 5:00 PM EST - 2 years ago

embecta to Participate in the 11th Annual BTIG MedTech Conference

Jan 24, 2024, 5:00 PM EST - 2 years ago

embecta to Report Fiscal First Quarter 2024 Financial Results

Jan 10, 2024, 5:15 PM EST - 2 years ago

Embecta Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 6:00 AM EST - 2 years ago

embecta Announces FDA 510(k) Submission for Insulin Patch Pump

Dec 14, 2023, 5:00 PM EST - 2 years ago

embecta to Participate at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 6:00 AM EST - 2 years ago

No embecta-made syringes impacted by FDA safety communication

Nov 29, 2023, 5:00 PM EST - 2 years ago

embecta to Participate in Investor Conferences

LordWorld May. 13 at 8:56 PM

0 · Reply

LordWorld May. 13 at 8:52 PM

$EMBC The probability of bankruptcy by the end of the year is 1%. 😂

0 · Reply

JOHNNY_DANGER May. 13 at 8:29 PM

$EMBC Is it possible that they file for chapter 7 bk by years end ?

1 · Reply

assetmogul2 May. 13 at 8:03 PM

$EMBC holding 170k shares and will decide what I am doing after hearing this speech tonight

0 · Reply

javiarza May. 13 at 7:59 PM

$EMBC 500 shares at 3,13$ - average down. Let’ s see the conference now!

0 · Reply

derdo May. 13 at 7:54 PM

$EMBC as i said, garbage

0 · Reply

OrangeJoolius May. 13 at 7:51 PM

$EMBC As I said, max short.

2 · Reply

showmethemoney75 May. 13 at 7:47 PM

$EMBC

0 · Reply

derdo May. 13 at 7:42 PM

$EMBC me warned but nobody listened. garbage

0 · Reply

LordWorld May. 13 at 7:33 PM

$EMBC I'm betting on this conference! Which will begin immediately after the market closes.

0 · Reply

LordWorld May. 13 at 7:24 PM

$EMBC ✊✊✊

0 · Reply

LuckyStar77 May. 13 at 6:47 PM

$EMBC Added more at 3.17. This is definitely not a risk-free trade, but I still see a real turnaround setup here. The company has an established global diabetes care business, strong institutional ownership, and is moving beyond its legacy insulin delivery products with its recent acquisition. Revenue pressure is real, but at these levels, I believe a lot of bad news may already be priced in. Hopefully I’m right, but we’ll see. Holding and waiting. 🚀⭐

1 · Reply

showmethemoney75 May. 13 at 6:30 PM

$EMBC

1 · Reply

Wonderfulnewz May. 13 at 6:26 PM

$EMBC the problem with these guys is the $1.3 billion in debt and a forecast to see sales shrink by 7% in 2026. They have an infrastructure based on flat growth so it’s negative operating leverage. Add to that an acquisition and the issues that come with that. It’s probably worth $3-4 but it’s not a pretty picture

1 · Reply

AlarmedSheiky May. 13 at 5:09 PM

$EMBC New silver lining! I feel comfortable taking profit on a bunch of short term winners because I know I have this hideous beast to unload come tax season!

2 · Reply

derdo May. 13 at 4:51 PM

$EMBC looks like time to short until 2.50.

1 · Reply

showmethemoney75 May. 13 at 4:40 PM

$EMBC Where is the 100 million buyback If they were executing it this would not be going in the dumpsters still. Why not now unless they feel it will fall more or worst yet they were never really going to….?????

2 · Reply

ALag77 May. 13 at 3:59 PM

$EMBC 'Max' shorting at ATL's, right after an already 65% dump? This thing can just as easily pop up, as much as it can creep more down. I'm in @ 3.17.... I'll risk the buy side on this one.

2 · Reply

OrangeJoolius May. 13 at 3:43 PM

$EMBC I'm max short here, the company is trash until the management does something to stem the tide. Shorts are well in control and if you can't beat them, join them.

2 · Reply

Xxxxcccemre May. 13 at 3:30 PM

$EMBC worst investment ever ….. I first bought in here at 5.20 and averaged down and averaged down 😂andddd averaged down thinking it was the bottom …. NOPE

2 · Reply

Gena45 May. 13 at 3:12 PM

$EMBC This is crazy Not even a bounce Holding 2k @$3.85 😬

2 · Reply

LordWorld May. 13 at 2:55 PM

$EMBC Buy back!

0 · Reply

Market Cap	199.34M
Revenue (ttm)	1.08B
Net Income (ttm)	95.40M
EPS (ttm)	N/A
PE Ratio	1.40
Forward PE	2.30
Profit Margin	8.83%
Debt to Equity Ratio	-2.12

Volume	4,904,188
Avg Vol	1,641,046
Day's Range	N/A - N/A
Shares Out	59.33M
Stochastic %K	3%
Beta	1.09
Analysts	Hold
Price Target	$8.00